This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: February 28, 2013
Last updated: November 1, 2016
Last verified: November 2016
This open-label, randomized, 2-way crossover study will assess the absolute bioavailability and pharmacokinetics of RO6811135 in healthy male volunteers. Subjects will be randomized to one of the sequences AB or BA to receive single doses of subcutaneous (A) or intravenous (B) RO6811135, with a washout period of at least 7 days between dosing.

Condition Intervention Phase
Healthy Volunteer Drug: RO6811135 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Open Label, Randomized, 2 Way-crossover Study to Investigate the Absolute Bioavailability and Pharmacokinetics of RO6811135, Following Single Dose Administration by Subcutaneous and Intravenous Route in Healthy Subjects.

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Absolute bioavailability of RO6811135 after subcutaneous administration: Area under the concentration-time curve (AUC) [ Time Frame: 48 hours ]

Secondary Outcome Measures:
  • Safety: Incidence of adverse events [ Time Frame: approximately 5 weeks ]
  • Pharmacodynamics: Fasting serum glucose/serum insulin [ Time Frame: 48 hours ]
  • Nausea scale: Visual analogue scale [ Time Frame: 48 hours ]

Enrollment: 12
Study Start Date: May 2013
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A: RO6811135 s.c. Drug: RO6811135
Single subcutaneous dose
Active Comparator: B: RO6811135 i.v. Drug: RO6811135
Single intravenous dose


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male healthy volunteers, 18-45 years of age inclusive
  • Healthy as determined by screening assessments
  • Body mass index (BMI) between 18-30 kg/m2

Exclusion Criteria:

  • Any clinically relevant history or the presence of respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological or connective tissue disease or diseases
  • History of anaphylaxis or severe systemic hypersensitivity or allergic reactions
  • Any history of alcohol and/or drug of abuse addiction during the past 5 years
  • Smoking more than 5 cigarettes a day or the equivalent amount of tobacco
  • Any clinically relevant abnormal test results prior to first dosing
  • Positive for hepatitis B, hepatitis C or HIV infection
  • Participation in an investigational drug or device study within 3 months prior to Day -1 of Period 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01802853

United Kingdom
Leeds, United Kingdom, LS2 9LH
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01802853     History of Changes
Other Study ID Numbers: BP28438
2012-005773-31 ( EudraCT Number )
Study First Received: February 28, 2013
Last Updated: November 1, 2016 processed this record on August 22, 2017